# Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

> **NCT04361370** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Yonsei University** · enrollment: 44 (estimated)

## Conditions studied

- Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer

## Interventions

- **DRUG:** Olaparib-Pembrolizumab-Bevacizumab

## Key facts

- **NCT ID:** NCT04361370
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-10-28
- **Primary completion:** 2026-05
- **Final completion:** 2026-08
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361370, "Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04361370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*